La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Markforged Holding Corp Warrants (17/08/2025) a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Markforged Holding Corp Warrants (17/08/2025)..

Markforged Holding Corp Warrants (17/08/2025) (OTC:MKFGW) Azioni, Catena delle Opzioni

Barrington Research analyst Michael Petusky maintains Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) with a Outperform and maintains $38 price target.

News

Price Target

Analyst Ratings

OPCH

Barrington Research Maintains Outperform on Option Care Health, Maintains $38 Price Target

President Donald Trump is <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46269036/scott-bessent-says-tariff-rates-set-to-boomerang-back-in-august-for-countries-faili">sticking to his Aug. 1 deadline</a> to reimpose steep tariffs, but the stock market doesn&#8217;t seem too worried. On Reddit&#8217;s <a href="https://www.reddit.com/r/stocks/comments/1luos7o/so_why_is_the_stock_market_completely_ignoring/">r/stocks</a>, one confused investor posted, &#8220;Trump just announced plans to do <a href="https://www.benzinga.com/markets/25/05/45486508/scott-bessent-signals-liberation-day-2-0-coming-if-countries-dont-sign-trade-deals-president-trump-has-put-them-on-notice">Liberation Day 2.0</a> all over again, but this time the stock market stays&#8230; up??? Does Wall Street simply not care about the economy anymore?&#8221;
<h2 class="wp-block-heading">Markets Shrug Off Tariff Threats</h2>
Wall Street dipped slightly on Tuesday, with the <a href="https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-slip-as-trump-stays-firm-on-august-tariff-deadline-announces-copper-duties-200133528.html">Dow falling</a> about 0.4% and the S&amp;P 500 slipping just 0.07%. The Nasdaq barely edged higher. These modest moves followed Trump&#8217;s declaration on <a href="https://truthsocial.com/@realDonaldTrump/posts/114818149310161097">Truth Social</a> that there would be &#8220;no extensions granted&#8221; beyond the Aug. 1 deadline, adding that countries should expect to start paying new tariffs on that day. He also announced a <a href="https://www.benzinga.com/markets/equities/25/07/46305321/copper-price-surges-trump-tariffs-stocks-july-2025">50% tariff on copper imports</a> and threatened tariffs as high as 200% on pharmaceuticals.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Despite the tough talk, many investors aren't reacting the <a href="https://www.benzinga.com/25/04/44710082/trumps-liberation-day-tariffs-wipe-out-174-billion-from-the-net-worth-of-worlds-top-10-billionaires-including-warren-buffett">way they did</a> when Trump tariffs were announced on April 2, a date he referred to as &#8220;Liberation Day&#8221;.
One Reddit user boiled it down like this: &#8220;Because no one is believing the boy who cried tariff.&#8221;
That skepticism is widespread. In the Reddit thread, a term kept popping up: TACO, short for &#8220;Trump Always Chickens Out.&#8221; It&#8217;s <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46180782/trumps-tariff-clock-ticks-but-taco-traders-arent-losing-their-cool">Wall Street slang</a> that reflects a belief that Trump often makes bold announcements but backs down before serious consequences hit. &#8220;It took him like an hour yesterday to start saying that the new date isn&#8217;t 100%,&#8221; another commenter noted.
Others pointed out that the market has already priced in much of the tariff risk. &#8220;When he threatened with a +50% range, the market panicked. Now the tariffs are landing in the range that the market initially anticipated,&#8221; one top commenter explained, referencing the expected 10% to 25% tariff range.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Even Trump's newly announced copper tariff pushed futures up more than 10%, while pharmaceutical stocks like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) pulled back after an early rally. Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) also <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46302633/amazon-stock-slips-as-early-prime-day-sales-data-disappoints">slipped</a> about 1% as its extended Prime Day began, with some investors watching for signs that tariffs are inflating consumer prices.
Still, some think the market is underestimating the damage. &#8220;We won't really know the impact until the fall,&#8221; one Reddit investor cautioned, suggesting that companies might temporarily absorb costs before passing them on.
In short, traders may have grown numb to Trump's tariff threats. &#8220;The market believes Trump isn&#8217;t serious and will back down before any real consequences emerge,&#8221; one commenter said. Another added: &#8220;Eventually he won&#8217;t chicken out,&#8221; hinting that investor complacency could backfire if Trump follows through this time.
For now, Wall Street appears more focused on Federal Reserve policy and the upcoming Q2 earnings season.&nbsp;
As one Redditor put it, &#8220;The stock market isn&#8217;t the economy.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence. </a></li>
</ul>
Image: Shutterstock

AMGN

AMZN

An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'

<a href="https://x.com/MarkKleinmanSky/status/1943373185652568509" title="https://x.com/MarkKleinmanSky/status/1943373185652568509">https://x.com/MarkKleinmanSky/status/1943373185652568509</a>

FLUT

Sky News Reporter Mark Kleinman Posts On X "Exclusive: Flutter Entertainment, the group behind Paddy Power and Betfair, is in advanced talks to buy a further 5pc stake in FanDuel, the US-based sports betting company, from Boyd Gaming in a deal expected to be worth close to $2B. An agreement could be announced this week."

Deutsche Bank analyst Chris Woronka maintains Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) with a Buy and raises the price target from $130 to $196.

Deutsche Bank Maintains Buy on Avis Budget Gr, Raises Price Target to $196

Barrington Research analyst Gary Prestopino maintains Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) with a Outperform and maintains $16 price target.

Barrington Research Maintains Outperform on Stoneridge, Maintains $16 Price Target

SoFi Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) has seen its stock soar by approximately <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46284237/sofi-ready-to-capture-the-opportunity-as-trumps-big-beautiful-plan-restricts-federal-student-loans" rel="noreferrer noopener">45% in the past month</a>, fueled by potential legislative changes that could significantly reroute student loan demand from federal programs to private lenders.
A proposed bill aiming to limit federal student loans for graduate students, particularly by ending the Graduate PLUS loan program, presents a multi-billion dollar opportunity for fintech companies like SoFi.
Specifically, Bank of America Securities (BofA) analyst Reginald Smith highlights President Donald Trump&#8217;s &#8220;One Big Beautiful Bill Act&#8221; (OBBBA) as a key catalyst. The proposed legislation aims to curtail federal student loans for graduate students by ending <a target="_blank" href="https://www.benzinga.com/news/politics/25/07/46290300/student-loan-forgiveness-faces-new-restrictions-under-trumps-pslf-overhaul-report" rel="noreferrer noopener">the Graduate PLUS loan program</a> and imposing stricter borrowing limits on other graduate programs.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46317067/cant-buy-spacex-stock-sofi-just-opened-the-backdoor-and-it-starts-at-10" rel="noreferrer noopener">Can&#8217;t Buy SpaceX Stock? SoFi Just Opened The Backdoor — And It Starts At $10</a>
Should this bill pass, it could shift up to $14 billion in student loan demand from the federal government to private lenders. Such a move could translate into considerable gains for companies like SoFi and Sallie Mae, potentially generating up to $700 million in loan origination fees and an additional $1.8 billion in annual interest income.
However, the full $14 billion may not entirely flow into private lending, as not all loans might qualify, and the bill also proposes raising federal loan limits for professional programs like law and medical school, which could temper some demand for private alternatives.
While SoFi has traditionally focused on refinancing loans for post-graduate individuals, the market for private loans taken by students still in graduate school is currently smaller, estimated at around $1 billion annually. This segment is largely dominated by Sallie Mae and Navient Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>), which collectively account for over 80% of these loans.
Despite its smaller current footprint in this specific niche, SoFi is well-positioned to capitalize on any market shift. The company frequently appears on loan-comparison websites and university preferred-lender lists, crucial channels for attracting new in-school borrowers.
BofA analysis suggests that if SoFi were to capture an additional 10 percentage points of the privatized Graduate PLUS market starting in July 2026, it could add approximately $1.4 billion in new loan originations.
This, in turn, could translate to roughly $70 million in origination fees and $200 million in interest income, representing about a 6% boost to BofA&#8217;s 2027 revenue outlook. Furthermore, a reduction in low-cost federal graduate loans would likely empower private lenders, including SoFi, to adjust pricing and potentially increase profitability.
SoFi&#8217;s financial trajectory also appears robust independently, with CFO Chris Lapointe projecting over $3 billion in adjusted <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46030175/sofi-stock-rises-this-week-amid-bullish-guidance-whats-going-on" rel="noreferrer noopener">net revenue by 2025</a> and annual revenue growth exceeding 25% through 2026. Adding to its diversified offerings, SoFi announced in June its plans to re-enable members to buy, sell, and store popular digital currencies like Bitcoin (CRYPTO: BTC/USD) and Ethereum (CRYPTO: ETH/USD) <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46117473/sofi-stock-gets-supercharged-with-return-to-crypto" rel="noreferrer noopener">later this year</a>.
&#8220;We like SOFI&#8217;s positioning and go-to-market strategy and think the company will ultimately be a winner in the neo/digital bank space and could eventually become the American Express of fintech,&#8221; noted the Bank of America analyst in a Thursday investor note. BofA maintains a Neutral rating on SoFi stock with a <a target="_blank" href="https://www.benzinga.com/quote/SOFI/analyst-ratings" rel="noreferrer noopener">price forecast of $16</a>.
Price Action: SOFI stock is trading higher by 3.54% to $20.93 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/07/46347218/coreweave-grabs-core-scientific-yet-rising-expenses-fuel-doubt" target="_blank" rel="noreferrer noopener">CoreWeave Grabs Core Scientific—Yet Rising Expenses Fuel Doubt</a></li>
</ul>
Image via Shutterstock

Analyst Color

Fintech news covering the emerging Financial Technology services sector

Fintech

Reiteration

Movers

Trading Ideas

General

NAVI

SOFI

How Trump's Student Loan Reform Could Funnel Billions In Loans To SoFi

Deutsche Bank analyst Bryan Kraft initiates coverage on Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) with a Buy rating and announces Price Target of $36.

Initiation

Deutsche Bank Initiates Coverage On Cinemark Holdings with Buy Rating, Announces Price Target of $36

<a href="https://www.federalreserve.gov/newsevents/pressreleases/bcreg20250710a.htm" title="https://www.federalreserve.gov/newsevents/pressreleases/bcreg20250710a.htm">https://www.federalreserve.gov/newsevents/pressreleases/bcreg20250710a.htm</a>

Macro Economic Events

Economics

Federal Reserve

Federal Reserve Board Requests Comment On Targeted Proposal To Revise Its Supervisory Rating Framework For Large Bank Holding Companies To Address The "Well Managed" Status Of These Firms

Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and raises the price target from $54 to $55.

HRMY

Deutsche Bank Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $55

Macquarie analyst Paul Golding downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Outperform to Neutral and maintains the price target from $15 to $15.

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

Macquarie Downgrades Core Scientific to Neutral, Maintains Price Target to $15

Deutsche Bank analyst Melissa Weathers initiates coverage on Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy rating and announces Price Target of $150.

Deutsche Bank Initiates Coverage On Micron Technology with Buy Rating, Announces Price Target of $150

Goldman Sachs analyst Corinne Johnson reinstates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and announces $55 price target.

Goldman Sachs Reinstates Buy on Avidity Biosciences, Announces $55 Price Target

As the race for satellite internet heats up, major players like Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are staking their claim in a market projected to be worth <a href="https://www.benzinga.com/news/space/25/06/46012441/amazon-retrains-warehouse-workers-for-satellite-jobs-it-really-is-life-changing-says-project-kuiper-technician">$40 billion by 2030.</a>
Bank of America Securities analyst Justin Post <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained a Buy</a> on Amazon with a price forecast of $248 on Thursday.
Project Kuiper has remained a top management growth initiative despite Amazon&#8217;s cost-focused agenda, and satellite launches began in the second quarter, Post noted. On its Website, Amazon has indicated that it expects to offer consumer service in late 2025, though timing is still uncertain, the analyst said.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46252872/why-amazon-lags-its-peers-in-2025" rel="noreferrer noopener">Why Amazon Lags Its Peers In 2025</a>
In his report, the analyst refreshed his views on launch costs and near-term expense impact from network build, the Project Kuiper business, potential synergies with Amazon, competitive landscape, revenue potential, and potential subscriber breakeven level assuming a 5-year satellite replacement cycle.
Amazon&#8217;s FCC license calls for 1,618 satellites to be deployed by July 2026, though Post noted an extension is possible given launch delays. Amazon completed the first two launches with 54 satellites in the second quarter of 2025, and the analyst expects an accelerated launch rate in the second half of 2025 (3 launches in the third quarter) and 2026.
He estimated that Amazon could spend $23 billion to build its entire constellation, using various public industry estimates, excluding consumer equipment costs.
In the near term, Post estimated over $600 million in constellation expense in the second quarter, ramping to ~$800 million in the third quarter and then growing to $1.1 billion in the fourth quarter of 2025 (before capitalization starts in the first quarter of 2026).
Amazon&#8217;s website indicates that consumer availability could begin in the fourth quarter, but a delay seems possible, the analyst said. He also had a scenario where capitalization starts later, in the third quarter of 2026.
He noted that 2.6 billion people globally lack broadband internet access, and BCG sees a $40 billion 2030 revenue potential for the global satellite communications service market.
Based on Post&#8217;s market assumptions, and assuming Amazon has just a 30% consumer share (Starlink already has 6 million subscribers), the analyst noted a $7.1 billion 2032 revenue potential for Amazon.
He also expects Kuiper to have synergies with Amazon&#8217;s logistics network, and the project to generate additional revenues from AWS&#8217;s enterprise and government customers. Post noted a compelling opportunity and potentially strong long-term margins given high start-up costs.
Post projected fiscal 2025 sales of $696.81 billion and EPS of $6.07.
AMZN Price Action: Amazon.com shares were up 0.09% at $222.75 at the time of publication Thursday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46333941/meta-has-gained-26-in-2025-can-the-rally-continue" target="_blank" rel="noreferrer noopener">Meta Has Gained 26% In 2025, Can The Rally Continue?</a></li>
</ul>
Photo: Shutterstock

Tech

How Project Kuiper Could Reshape Amazon's Future, Tap Into $40 Billion Demand

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) supplemental Biologics License Application (sBLA) for Spikevax, the company&#8217;s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.
The company&#8217;s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46168811/modernas-mrna-flu-vaccine-outperforms-standard-shots" rel="noreferrer noopener">Moderna&#8217;s mRNA Flu Vaccine Outperforms Standard Shots</a>
&#8220;COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,&#8221; said Stéphane Bancel, CEO of Moderna. &#8220;We appreciate the FDA&#8217;s diligent scientific review and approval of Spikevax for pediatric populations at increased risk for COVID-19 disease.&#8221;
Moderna<a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx" rel="noreferrer noopener"> expects</a> to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) have requested that London's Court of Appeal reverse a previous decision that found their COVID-19 vaccine to be in violation of a Moderna patent.
In July 2024, the High Court's ruling declared one of Moderna's mRNA technology patents invalid but upheld another, confirming that Pfizer and BioNTech's Comirnaty <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" rel="noreferrer noopener">vaccine had infringed on it</a>.
Reuters reported that Pfizer and Moderna are trying to challenge a ruling that upheld a patent, after Judge Richard Meade allowed them to appeal his decision.
They argue that Moderna&#8217;s mRNA technology was simply a clear next step based on earlier research, so the patent shouldn&#8217;t be valid. However, Moderna believes the judge made the right decision and that the ruling should remain in place.
An alliance of medical and public health organizations filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.
The plaintiffs contend that Kennedy has launched an "assault on science, public health, and evidence-based medicine" through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children <a href="https://www.benzinga.com/news/health-care/25/07/46303191/medical-groups-sue-rfk-jr-for-assault-on-science-over-unlawful-covid-19-vaccine-rollbacks" target="_blank" rel="noreferrer noopener">and pregnant individuals</a>.
According to a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration's (FDA) top vaccine official, overruled agency scientists to limit the approval of two COVID-19 vaccines, despite internal recommendations to clear <a href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" target="_blank" rel="noreferrer noopener">them for broader use</a>.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna for individuals aged 12 and older, citing favorable risk-benefit analyses.
But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" rel="noreferrer noopener">the balance of risks and benefits</a>.
Price Action: MRNA stock is up 3.60% at $33.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/07/46345543/klotho-stock-delivers-1222-biotech-blowout-opportunity-or-bubble" target="_blank" rel="noreferrer noopener">Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble?</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

BNTX

MRNA

NVAX

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

Goldman Sachs analyst Corinne Johnson reinstates ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and announces $33 price target.

AVBP

Goldman Sachs Reinstates Buy on ArriVent BioPharma, Announces $33 Price Target

Goldman Sachs analyst Corinne Johnson reinstates Amylyx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) with a Buy and announces $10 price target.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Goldman Sachs Reinstates Buy on Amylyx Pharmaceuticals, Announces $10 Price Target

HSCS

HeartSciences Shares Halted On Circuit Breaker To The Downside, Stock Now Up 19.0%

CIGL

Concorde International Group Shares Halted On Circuit Breaker, Stock Now Down -86.5%

B. Riley Securities analyst Lucas Pipes maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $15 to $22.

IREN

B. Riley Securities Maintains Buy on IREN, Raises Price Target to $22

B. Riley Securities analyst Nick Giles maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and lowers the price target from $3 to $2.

B. Riley Securities Maintains Buy on Canaan, Lowers Price Target to $2

Markforged Holding Corp Warrants (17/08/2025)

Comments

Markforged Holding Corp Warrants (17/08/2025)

Markforged Holding Corp Warrants (17/08/2025) (MKFGW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO